AstraZeneca's China partner expects to be able to make 400 million COVID-19 vaccine doses a year
AstraZeneca's China partner expects to be able to make 400 million COVID-19 vaccine doses a year Reuters 2/02/2021 © Reuters/LEE SMITH FILE PHOTO: COVID-19 vaccinations in Newcastle upon Tyne BEIJING (Reuters) - China's Shenzhen Kangtai Biological Products said on Tuesday it had completed a facility designed to be able to produce 400 million doses of AstraZeneca's COVID-19 vaccine per year, doubling a capacity target promised in 2020. "Kangtai is actively pushing forward procedures for the vaccine's clinical trial and registration in China, and has completed a manufacturing plant and s...